Patents by Inventor Dave S. B. Hoon

Dave S. B. Hoon has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20120088683
    Abstract: A method of detecting circulating melanoma or carcinoma cells in a subject. The method comprises obtaining a body fluid from a subject and detecting the expression of a panel of genes in the body fluid, wherein the expression of the panel of genes indicates the presence of circulating melanoma or carcinoma cells in the subject. Genes useful for detecting melanoma cells includes GalNAc-T, MAGE-A3, MART-1, PAX-3, and TRP-2; genes useful for detecting carcinoma cells include C-Met, MAGE-A3, Stanniocalcin-1, Stanniocalcin-2, mammaglobin, HSP27, GalNAc-T, CK20, and ?-HCG. Also disclosed are kits containing agents for detecting the expression of these genes.
    Type: Application
    Filed: October 2, 2011
    Publication date: April 12, 2012
    Applicant: John Wayne Cancer Institute
    Inventor: Dave S. B. Hoon
  • Patent number: 8039218
    Abstract: A method of detecting circulating melanoma or carcinoma cells in a subject. The method comprises obtaining a body fluid from a subject and detecting the expression of a panel of genes in the body fluid, wherein the expression of the panel of genes indicates the presence of circulating melanoma or carcinoma cells in the subject. Genes useful for detecting melanoma cells includes GalNAc-T, MAGE-A3, MART-1, PAX-3, and TRP-2; genes useful for detecting carcinoma cells include C-Met, MAGE-A3, Stanniocalcin-1, Stanniocalcin-2, mammaglobin, HSP27, GalNAc-T, CK20, and ?-HCG. Also disclosed are kits containing agents for detecting the expression of these genes.
    Type: Grant
    Filed: September 14, 2005
    Date of Patent: October 18, 2011
    Assignee: John Wayne Cancer Institute
    Inventor: Dave S. B. Hoon
  • Publication number: 20110212444
    Abstract: The invention relates to a method of detecting melanoma or breast cancer using DNA methylation in MINT17, MINT31, or the promoter region of WIF1, TFPI2, RASSF1A, SOCS1, GATA4, or RAR?2 as a biomarker. Also disclosed are methods of using the biomarker for determining the cancer status and predicting the outcome of the cancer.
    Type: Application
    Filed: December 29, 2010
    Publication date: September 1, 2011
    Inventors: Dave S.B. Hoon, Atsushi Tanemura, Anneke van Hoesel
  • Publication number: 20110207136
    Abstract: The invention provides a quantitative realtime RT-PCR assay for detection of metastatic breast, gastric, pancreas or colon cancer cells or metastatic melanoma. The assay allows to predict disease recurrence and survival in patients with AJCC stage I and II, and III disease using multimarker panels. The method for detecting metastatic melanoma cells utilizes panels of markers selected from a group consisting of MAGE-A3, GalNAcT, MART-1, PAX3, Mitf, TRP-2, and Tyrosinase. The method for detecting metastatic breast, gastric, pancreas or colon cancer cells in paraffin-embedded samples utilizes panels of markers selected from a group consisting of C-Met, MAGE-A3, Stanniocalcin-1, mammoglobin, HSP27, GalNAcT, CK20, and ?-HCG.
    Type: Application
    Filed: January 12, 2011
    Publication date: August 25, 2011
    Applicant: JOHN WAYNE CANCER INSTITUTE
    Inventors: Dave S. B. Hoon, Hiroya Takeuchi
  • Publication number: 20110206705
    Abstract: B7H3 is a ligand member of the immunoregulatory family of proteins on immune cells. In one embodiment, a method for diagnosing the progression of cancer with a high propensity of primary tumor metastasis to the lymph node or distant site is provided. Such a method may comprise obtaining a cancer tissue sample from a cancer patient, determining an expression level of B7-H3 present in the tissue sample, and diagnosing the progression of the cancer having a high propensity of primary tumor metastasis to the lymph node or distant site based upon the expression level, wherein an increased expression level correlates with an increased probability of having regional lymph nodes or organ site that are positive for metastases.
    Type: Application
    Filed: December 27, 2010
    Publication date: August 25, 2011
    Inventor: Dave S.B. HOON
  • Publication number: 20110195499
    Abstract: The invention relates to a method of detecting a RET mutant in a melanoma cell. Also disclosed is a method of modulating the activity of a RET mutant in a melanoma cell with an agent that interferes with the activity of the RET mutant.
    Type: Application
    Filed: December 29, 2010
    Publication date: August 11, 2011
    Inventors: DAVE S.B. HOON, NORIHIKO NARITA, ATSUSHI TANEMURA
  • Publication number: 20110171660
    Abstract: The invention relates to methods for determining whether a melanoma will metastasize or has metastasized to the small intestine in a subject by detecting or quantifying the expression of the CCR9, CCL25/TECK, or integrin ?4 gene. Also disclosed are methods for treating subjects so identified.
    Type: Application
    Filed: December 30, 2010
    Publication date: July 14, 2011
    Inventors: Dave S. B. Hoon, Farin Amersi
  • Publication number: 20110171240
    Abstract: The invention relates to methods for determining whether a melanoma will metastasize or has metastasized to the small intestine in a subject by detecting or quantifying the expression of the CCR9, CCL25/TECK, or integrin ?4 gene. Also disclosed are methods for treating subjects so identified.
    Type: Application
    Filed: December 30, 2010
    Publication date: July 14, 2011
    Inventors: Dave S. B. Hoon, Farin Amersi
  • Publication number: 20110171632
    Abstract: A method of detecting DNA markers in the 12q22-23 region. The method comprises providing a sample containing acellular DNA from a subject and detecting one or more DNA markers in the 12q22-23 region in the sample. Also disclosed are methods of diagnosing and monitoring cancer; methods of determining the efficacy of a therapy, and the probabilities of survival and responsiveness to a therapy; and packaged products for using these methods.
    Type: Application
    Filed: December 29, 2010
    Publication date: July 14, 2011
    Inventors: Akihide FUJIMOTO, Dave S.B. Hoon
  • Publication number: 20110159502
    Abstract: The invention relates to a method of detecting LINE-1 (long interspersed nucleotide elements-1) DNA either methylated or unmethylated at the promoter region in a tissue or body fluid sample from a subject. Also disclosed are methods of using LINE-1 DNA as a biomarker for diagnosing, predicting, and monitoring cancer progression and treatment.
    Type: Application
    Filed: December 30, 2010
    Publication date: June 30, 2011
    Inventors: Dave S.B. Hoon, Eiji Sunami
  • Publication number: 20110159509
    Abstract: The invention relates to methods for cancer diagnosis, prognosis, and treatment based on the expression or activity levels of RUNX3 and miR-532-5p. Also disclosed is a method of reducing the inhibition of RUNX3 by miR-532-5p with an agent that interferes with the interaction between RUNX3 and miR-532-5p transcripts.
    Type: Application
    Filed: December 14, 2010
    Publication date: June 30, 2011
    Inventors: Dave S.B. Hoon, Minoru Kitago
  • Publication number: 20110159501
    Abstract: The invention relates to a method of detecting LINE-1 (long interspersed nucleotide elements-1) DNA either methylated or unmethylated at the promoter region in a tissue or body fluid sample from a subject. Also disclosed are methods of using LINE-1 DNA as a biomarker for diagnosing, predicting, and monitoring cancer progression and treatment.
    Type: Application
    Filed: December 30, 2010
    Publication date: June 30, 2011
    Inventors: Dave S.B. Hoon, Eiji Sunami
  • Publication number: 20110158975
    Abstract: The invention relates to methods for cancer diagnosis, prognosis, and treatment based on the expression or activity levels of RUNX3 and miR-532-5p. Also disclosed is a method of reducing the inhibition of RUNX3 by miR-532-5p with an agent that interferes with the interaction between RUNX3 and miR-532-5p transcripts.
    Type: Application
    Filed: December 14, 2010
    Publication date: June 30, 2011
    Inventors: Dave S.B. Hoon, Minoru Kitago
  • Publication number: 20110159510
    Abstract: The invention relates to a method of detecting LINE-1 (long interspersed nucleotide elements-1) DNA either methylated or unmethylated at the promoter region in a tissue or body fluid sample from a subject. Also disclosed are methods of using LINE-1 DNA as a biomarker for diagnosing, predicting, and monitoring cancer progression and treatment.
    Type: Application
    Filed: December 30, 2010
    Publication date: June 30, 2011
    Inventors: Dave S.B. Hoon, Eiji Sunami
  • Publication number: 20110151465
    Abstract: The invention relates to a method of detecting LINE-1 (long interspersed nucleotide elements-1) DNA either methylated or unmethylated at the promoter region in a tissue or body fluid sample from a subject. Also disclosed are methods of using LINE-1 DNA as a biomarker for diagnosing, predicting, and monitoring cancer progression and treatment.
    Type: Application
    Filed: December 30, 2010
    Publication date: June 23, 2011
    Inventors: Dave S.B. Hoon, Eiji Sunami
  • Publication number: 20110124004
    Abstract: HMW-MAA antibody cocktails and their uses in detecting cancer and isolating cancer cells are disclosed. Also disclosed are methods of detecting cancer based on the presence of an HMW-MAA genomic sequence in circulating DNA, as well as the increased expression of the HMW-MAA gene and the reduced methylation of the HMW-MAA gene promoter in tissues and circulating cells.
    Type: Application
    Filed: December 30, 2010
    Publication date: May 26, 2011
    Inventors: Dave S.B. Hoon, Soldano Ferrone, Minoru Kitago, Yasufumi Goto
  • Publication number: 20110124007
    Abstract: HMW-MAA antibody cocktails and their uses in detecting cancer and isolating cancer cells are disclosed. Also disclosed are methods of detecting cancer based on the presence of an HMW-MAA genomic sequence in circulating DNA, as well as the increased expression of the HMW-MAA gene and the reduced methylation of the HMW-MAA gene promoter in tissues and circulating cells.
    Type: Application
    Filed: December 30, 2010
    Publication date: May 26, 2011
    Inventors: Dave S.B. Hoon, Soldano Ferrone, Minoru Kitago, Yasufumi Goto
  • Publication number: 20110123602
    Abstract: The present invention describes a method for identification and labeling of sentinel lymph nodes (SLNs) and the presence or absence of lymph node metastases as an important diagnostic and prognostic factor in early stage cancers of all types. The method, know as Molecular Lymphatic Mapping, uses traditional dye/radioactive tracer based techniques in conjunction with a nucleic acid marker to identify and label the SLN, not only for current diagnostic methods, but for archival purposes. In addition, MLM can be used to deliver a therapeutic gene or genes to the SLN to activate tumor immunity to tumor cells, and/or to inhibit tumor metastases. The methods may be combined with therapeutic intervention including chemotherapy and radiotherapy.
    Type: Application
    Filed: December 29, 2010
    Publication date: May 26, 2011
    Inventors: Dave S.B. Hoon, Bret Taback
  • Patent number: 7943319
    Abstract: The invention relates to a method of detecting a RET mutant in a melanoma cell. Also disclosed is a method of modulating the activity of a RET mutant in a melanoma cell with an agent that interferes with the activity of the RET mutant.
    Type: Grant
    Filed: November 7, 2008
    Date of Patent: May 17, 2011
    Assignee: John Wayne Cancer Institute
    Inventors: Dave S. B. Hoon, Norihiko Narita, Atsushi Tanemura
  • Publication number: 20110097727
    Abstract: A method is provided for assessing allelic losses and hypermethylation of genes in CpG tumor promotor region on specific chromosomal regions in cancer patients, including melanoma, neuroblastoma breast, colorectal, and prostate cancer patients. The method relies on the evidence that free DNA and hypermethylation of genes in CpG tumor promotor region may be identified in the bone marrow, serum, plasma, and tumor tissue samples of cancer patients. Methods of melanoma, neuroblastoma, colorectal cancer, breast cancer and prostate cancer detection, staging, and prognosis are also provided.
    Type: Application
    Filed: December 27, 2010
    Publication date: April 28, 2011
    Inventors: Dave S.B. HOON, Bret Taback